1. France Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
IntegraGen SA

IntegraGen SA

EEURONEXT:ALINT
0.07
EUR
+0.00
(+2.94%)
3.51MMarket Cap
Apr 28Next Earn
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
1.23
1.15
1.31
1.22
1.11
1.2
0.96
1.07
1.26
1.34
1.71
1.99
1.9
- -
Basic EPS, GAAP
-0.54
-0.42
-0.62
-0.21
-0.31
-0.33
-0.13
-0.18
-0.04
-0.06
- -
- -
-0.03
- -
Free Cash Flow per Basic Share
- -
-0.37
-0.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.82
0.79
0.17
0.76
0.58
0.26
0.61
0.43
0.38
0.32
0.33
0.33
0.3
0.29
Tangible Book Value per Share
0.82
0.79
0.17
0.76
0.58
0.26
0.61
0.43
0.38
0.32
0.33
0.33
0.3
0.29
Basic Weighted Avg Shares
4
4
4
5
5
5
6
6
7
7
7
7
7
7
Sales/Revenue/Turnover
5
5
5
6
6
6
6
7
8
9
11
13
13
- -
Operating Margin (%)
-54.31
-50.43
-54.08
-23.84
-42.84
-29.26
3.67
-16.94
-4.1
-1.88
-0.61
-0.53
-0.94
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-3
-1
-2
-2
-1
-1
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-43.88
-36.41
-47.07
-17.29
-27.47
-27.41
-13.8
-16.46
-3.44
-4.18
0.14
-0.03
-1.37
- -
Working Capital
4
4
2
5
4
2
4
3
3
1
2
3
3
2
LT Debt
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
1
- -
Total Equity
3
3
1
4
3
1
4
3
3
2
2
2
2
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-49.61
-54.53
-129.57
-46.86
-45.82
-78.32
-33.08
-33.9
-10.74
-16.03
0.71
-0.16
-8.17
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'23
Dec'23
Jun'24
ST Debt
1
- -
- -
LT Borrowings
- -
1
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
8
6
4

Working Capital

EUR

•

in mil. unless spec.
Jun'23
Dec'23
Jun'24
Total Current Assets
10
8
6
Cash, Cash Equivalents & STI
4
3
2
Accounts Receivable, Net
5
3
2
Inventories
1
- -
- -
Total Current Liabilities
8
5
4
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
51.21%
-6.2%
-7.85%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
449.71%
903.42%
4,787.34%
Sales/Revenue/Turnover
9.22%
13.13%
-4.78%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
13
2023
- -
- -
13
2024
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
-0.03
2024
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bernard Courtieu
Full Time Employees
37
Sector
Health services
Industry
Medical/Nursing services
Address
Genopole Campus 1 BAt. 8 Evry IF France 91000
IPO Date
Jun 18, 2010
Website
integragen.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
IntegraGen S.A. (ALINT.PA) specializes in genomic analysis services for researchers and clinicians, focusing on next-generation sequencing (NGS), bioinformatics, and biostatistics tools in oncology and rare genetic diseases; it offers DNA sequencing including whole genome, exome, and custom panels such as OncoDEEP pan-cancer panel; transcriptomics via RNA-Seq for gene expression analysis; epigenomics through methylation studies using RRBS, MethySeq, MeDIP, and ChIP-Seq; genotyping with Illumina Infinium arrays for pharmacogenomics and GWAS; and software tools like MERCURY for oncology data interpretation, Galileo for RNA-Seq exploration, and GeCo consulting. The company, founded in 2000 and headquartered at Genopole Campus 1, Evry, France, operates primarily in Europe through its NGS laboratory and serves academic, hospital, and biotech clients; it is a subsidiary of the Belgian OncoDNA Group, which extends to Spain, the UK, Germany, and a network of 35 international distributors. Recent developments include the operational launch of the UMBRELLA project in 2025, contributing to major project acceleration amid a 34% sales decline to €2.5 million in H1 2025 due to public research funding delays and biotech budget cuts; operating expenses fell 20% by mid-2025 with cash at €1.7-2.1 million, prompting exploration of financing options and cost reductions to extend runway beyond Q1 2026.